Search results for " medica"

showing 10 items of 35043 documents

Predicting the 2000‐m Rowing Ergometer Performance from Anthropometric, Maximal Oxygen Uptake and 60‐s Mean Power Variables in National Level Young R…

2020

Abstract Many studies reported various relationships between 2000-m rowing performance and anthropometric as well as metabolic variables, however, little is known about 60-s mean power in elite youth athletes. The aim of this study was to develop different regression models to predict 2000-m rowing indoor performance time (t2000) using anthropometric variables, maximal oxygen uptake (VO2max) and mean power established during a 60-s all-out test (W60) in national elite youth rowers. Fifteen youth male Italian rowers (age: 15.7 ± 2.0 years; body height: 176.0 ± 8.0 cm; body mass: 71.2 ± 10.0 kg) performed an incremental maximal test, a 60-s all-out test and a 2000-m race simulation using a Co…

rowing performanceelite youth athletesanthropometric variablesRowingelite youth athletes mean power indoor rowing anthropometric variables VO2max rowing performancePhysical Therapy Sports Therapy and Rehabilitationmean power030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinevo2maxPhysiology (medical)StatisticsLinear regressionindoor rowingNational levellcsh:Sports medicineMathematicsSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' SportivebiologyAthletesVO2 maxRegression analysis030229 sport sciencesSection II – Exercise Physiology & Sports MedicineAnthropometrybiology.organism_classificationStandard errorlcsh:RC1200-1245Settore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotorieJournal of Human Kinetics
researchProduct

Bartomeu de Tresbens, physician and astrologer in the service of king Peter the Ceremonious and the infant John: between the service to the Crown and…

2018

Bartomeu de Tresbens was a physician, astrologer and philosopher at the service of two kings of the Crown of Aragon, Peter IV the Ceremonious and his son, Duke John, the future John I the Hunter, between 1360 and 1375, approximately. His major work of astrological content has hardly been studied, except for the Llibre de les nativitats (Book of Nativities). Similarly, most of his biography is not known. The documents, which are mainly the correspondence of its relationship with the monarchy, are preserved, but also other records that connect him to the municipalities of Barcelona and Cervera. Particularly in the latter case, Tresbens was tempted by the municipal authorities for being the ph…

royal householdHistorymedicina medievalBiographyContext (language use)medieval medicinecontractecorona d’aragó06 humanities and the artsCrown of Aragonastrologia060104 historycasa reialHistory and Philosophy of ScienceMonarchyAZ20-999astrologyHistory of scholarship and learning. The humanities0601 history and archaeologySalarycontractHistory of medicine. Medical expeditionsHumanitiesR131-687Asclepio
researchProduct

Zaburzenia neurorozwojowe. Zmiany w podejściu teoretycznym i diagnostycznym

2019

Na potrzeby diagnozy i terapii powstały typologie medyczne o zasięgu ogólnoświatowym. Do najbardziej znanych i powszechnie stosowanych zalicza się ICD (ang. International Statistical Classification of Diseases and Related Health Problems) – Międzynarodową Statystyczną Klasyfikację Chorób i Problemów Zdrowotnych ICD oraz DSM (ang. Diagnostic and Statistical Manual of Mental Disorders) – Klasyfikację Zaburzeń Psychicznych DSM, których nowe edycje stanowią przedmiot zainteresowań autorek. W artykule wskazano światowe trendy i kierunki zmian, jakie się dokonują w obszarze terminologii i kategoryzowania zaburzeń rozwoju psychicznego (neurorozwojowych) i związanych z nimi rozwojowych zaburzeń jęz…

rozwojowe zaburzenia językalanguage and speech development disorderszaburzenia rozwoju psychicznegoICDneurodevelopmental disorderslanguage development disorderszaburzenia rozwoju mowy i językamental development disordersmiędzynarodowe klasyfikacje medyczne DSMzaburzenia neurorozwojoweinternational medical classifications DSMLogopedia
researchProduct

Study of the Strengths and Weaknesses of Nursing Work Environments in Primary Care in Spain

2021

Background: Nursing work environments are defined as the characteristics of the workplace that promote or hinder the provision of professional care by nurses. Positive work environments lead to better health outcomes. Our study aims to identify the strengths and weaknesses of primary health care settings in Spain. Methods: Cross-sectional study carried out from 2018 to 2019. We used the Practice Environment Scale of the Nursing Work Index and the TOP10 Questionnaire of Assessment of Environments in Primary Health Care for data collection. The associations between sociodemographic and professional variables were analyzed. Results: In total, 702 primary care nurses participated in the study. …

s roleHealth Toxicology and MutagenesisPsychological interventionlcsh:MedicinePrimary careNursingNursing Staff HospitalArticleprimary care03 medical and health sciences0302 clinical medicinenursingquality of health careNursingNurse’s roleHumansNurse Administrators030212 general & internal medicineHuman resourcesWorkplaceData collectionPrimary Health Care030504 nursingbusiness.industrylcsh:Rnurse’s rolePublic Health Environmental and Occupational HealthPrimary careWork environmentnurse&#8217workplaceCross-Sectional StudiesWork (electrical)SpainScale (social sciences)Quality of health careEnfermería0305 other medical sciencebusinessPsychologyStrengths and weaknesses
researchProduct

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea

2019

Background: Thyroid cancer has become the most common cancer in Korea. Generally, thyroid cancer patients have a good prognosis; however, 15–20% of patients experience recurrence or distant metastasis or are refractory to standard treatment. We assessed the safety of sorafenib and lenvatinib in patients with advanced or metastatic radioactive iodine-refractory differentiated thyroid cancers (DTC) consecutively treated at a tertiary center in South Korea.Methods: We retrospectively reviewed the charts of all consecutive patients with DTC treated during ≥6 months with lenvatinib (February 2016–April 2018) and sorafenib (January 2014–April 2018) at Gangnam Severance Hospital. Patients were tre…

safety0301 basic medicineSorafenibmedicine.medical_specialtyEndocrinology Diabetes and Metabolismdifferentiated thyroid cancerrefractory thyroid cancer030209 endocrinology & metabolismlenvatiniblcsh:Diseases of the endocrine glands. Clinical endocrinologyGastroenterologyPapillary thyroid cancer03 medical and health scienceschemistry.chemical_compoundEndocrinology0302 clinical medicineInternal medicinetyrosine kinase inhibitorsmedicineAdverse effectFollicular thyroid cancerThyroid cancerOriginal Researchlcsh:RC648-665business.industryStandard treatmentCancermedicine.disease030104 developmental biologychemistryadverse effectschart reviewsorafenibbusinessLenvatinibmedicine.drugFrontiers in Endocrinology
researchProduct

Online interventions to prevent mental health problems implemented in school settings: the perspectives from key stakeholders in Austria and Spain

2021

Abstract Background Schools are key settings for delivering mental illness prevention in adolescents. Data on stakeholders’ attitudes and factors relevant for the implementation of Internet-based prevention programmes are scarce. Methods Stakeholders in the school setting from Austria and Spain were consulted. Potential facilitators (e.g. teachers and school psychologists) completed an online questionnaire (N=50), policy makers (e.g. representatives of the ministry of education and health professional associations) participated in semi-structured interviews (N=9) and pupils (N=29, 14–19 years) participated in focus groups. Thematic analysis was used to identify experiences with, attitudes a…

safetyAdolescentpsychologistsPsychological interventionComputer-assisted web interviewingpupilhealth personnelprivacy03 medical and health sciences0302 clinical medicinepreventionHumansAcademicSubjects/MED00860AcademicSubjects/SOC01210030212 general & internal medicineadolescentsCurriculumschool (environment)School Health ServicesMedical educationInternetSchoolsteachersPart II: ICare Stakeholder SurveySchool psychologyPublic Health Environmental and Occupational HealthStakeholderFocus groupMental healthprevention programInternet-based intervention030227 psychiatrymental disordersMental HealthSpainattitudeAustriaThematic analysisPsychologyAcademicSubjects/SOC02610Internet-Based Interventionmental health
researchProduct

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in De…

2020

Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: O…

safetyAdultMalemedicine.medical_specialtyTime Factorsbiologic agentsprospective cohortlong-term follow-upDermatologyimmunosuppressive agentsanti-inflammatory agentsCohort Studies030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasisUstekinumabmedicineAdalimumabHumansPsoriasisRegistriesAdverse effectProspective cohort studyAgedbusiness.industryregistriespsoriasis/drug therapyanti-TNFMiddle Agedmedicine.diseaseInfliximabBiological TherapySpain030220 oncology & carcinogenesispharmacovigilanceadverse effectsSecukinumabFemaleApremilastbusinessmedicine.drugJournal of the American Academy of Dermatology
researchProduct

Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor

2020

Introduction: The discovery and the clinical availability of novel cyclin-dependent kinases 4 and 6 inhibitors have profoundly changed the therapeutic scenario of metastatic hormone receptor-positive breast carcinoma. Among these inhibitors, abemaciclib can induce potent and sustained cell cycle arrest and immune system stimulation. Areas covered: This review summarizes the safety profile and clinical efficacy data on abemaciclib alone or in combination with aromatase inhibitors or fulvestrant in metastatic hormone receptor-positive breast carcinoma. The management of patients treated with abemaciclib is the object of this paper. Expert opinion: As shown in phase 2 and 3 clinical trials on …

safetyAminopyridinesBreast Neoplasms030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundabemaciclib breast cancer metastases hormonal receptors safetybreast cancer0302 clinical medicineBreast cancerCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)metastasesskin and connective tissue diseasesFulvestrantProtein Kinase InhibitorsAbemaciclibbiologyAromatase Inhibitorsbusiness.industryKinasehormonal receptorsCyclin-Dependent Kinase 4Cell Cycle CheckpointsCyclin-Dependent Kinase 6General Medicinemedicine.diseaseAbemaciclibchemistry030220 oncology & carcinogenesisQuality of LifeCancer researchbiology.proteinBenzimidazolesFemalesense organsbusinessHormone
researchProduct

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

2016

Purpose The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients and methods Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 µg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Advers…

safetyCancer Researchmedicine.drug_classmedicine.medical_treatmentMedizinPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerimmunogenicityImmunostimulant03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerCancer immunotherapymedicine1506030304 developmental biologyOriginal ResearchPRAME antigen0303 health sciencesPRAMEcancer immunotherapybusiness.industryMelanomaImmunogenicityCancermedicine.disease3. Good healthOncology030220 oncology & carcinogenesisImmunologyChillsmedicine.symptombusinessmetastatic melanoma
researchProduct

Polyphenols and Pharmacological Screening of a Monarda fistulosa L. dry Extract Based on a Hydrodistilled Residue By-Product

2021

This study aimed to determine the composition and content of polyphenols in the dry extract obtained from the hydrodistilled residue by-product of the wild bergamot (Monarda fistulosa L., Lamiaceae Martinov family) herb (MFDE) and to evaluate its safety and pharmacological properties. The total phenolic content (TPC) in the MFDE was 120.64 mg GAE/g. The high-performance liquid chromatography (HPLC) analysis showed the presence of a plethora of phenolic compounds, including hydroxycinnamic acids and flavone derivatives in the MFDE, with rosmarinic acid and luteolin-7-O-glucoside being the main components. With an IC50 value of 0.285 mg/mL, it was found to be a strong DPPH radical scavenger. …

safetyDPPHRM1-950phenolic compoundsMonarda fistulosa01 natural sciencesHigh-performance liquid chromatographywild bergamot03 medical and health scienceschemistry.chemical_compound0302 clinical medicineantiradical activityPharmacology (medical)anti-inflammatory activityanalgesic activityOriginal ResearchPharmacologyResidue (complex analysis)biologyTraditional medicine010405 organic chemistryRosmarinic acidbiology.organism_classificationAcute toxicity0104 chemical scienceschemistryherbPolyphenol030220 oncology & carcinogenesispostdistillation wasteLamiaceaeTherapeutics. PharmacologyFrontiers in Pharmacology
researchProduct